

Box Seq
IFW

PATENT APPLICATION

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A86989

Rajeeva SINGH, et al.

Appln. No.: 10/729,441

Group Art Unit: 1641

Confirmation No.: 3309

Examiner: Unassigned

Filed: December 8, 2003

For: ANTI-IGF-I RECEPTOR ANTIBODIES

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In the Brief Description of the Figures of the instant application, the description of Figure 23 includes sequence identifiers for the EM164 v1.1 DNA (SEQ ID NO:93) and protein (SEQ ID NO:94) sequences, the EM164 v1.2 DNA (SEQ ID NO:95) and protein (SEQ ID NO:96) sequences, and the EM164 v1.3 DNA (SEQ ID NO:97) and protein (SEQ ID NO:98) sequences. However, due to an oversight, only sequences corresponding to SEQ ID NOs:93, 94, 95 and 97 were included in the Sequence Listing (SEQ ID NOs:93, 94, 95 and 96, respectively) filed in the instant application on August 25, 2004.

The substitute Sequence Listing being filed herewith corrects this error. Each of the six sequences noted in the description of Figure 23 is now included in the Sequence Listing. Support for the substitute Sequence Listing may be found in Figure 23 which shows each of the six sequences.


No new matter has been added.

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING
U.S. Appln. No. 10/729,441

A8689

Applicants respectfully request that the Examiner acknowledge that the substitute Sequence Listing meets the requirements of 37 C.F.R. §§1.821-1.825 and that the Examiner enter the substitute Sequence Listing.

Respectfully submitted,



Drew Hissong
Registration No. 44,765


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: October 27, 2005



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A86989

Rajeeva SINGH, et al.

Appln. No.: 10/729,441

Group Art Unit: 1641

Confirmation No.: 3309

Examiner: Unassigned

Filed: December 8, 2003

For: ANTI-IGF-I RECEPTOR ANTIBODIES

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

MAIL STOP SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In connection with the substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission does not include any new matter;
2. the contents of the 53-page substitute Sequence Listing being filed herewith, and the attached computer readable copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and
3. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that


STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

A8689
U.S. Appl. No. 10/729,441

such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Applicants respectfully request amendment of the application by entry of the substitute Sequence Listing into the application in place of the Sequence Listing filed August 25, 2004, in the application.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: October 27, 2005